603310-75-4

Usage

Uses

Used in Respiratory Medicine:
5-(1-Methylethyl)-2-pyridinamine is used as a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It works by blocking the action of acetylcholine, a neurotransmitter that causes constriction of the airways, thus allowing the muscles in the airways to relax and the airways to widen. This helps to alleviate symptoms such as wheezing, shortness of breath, and chest tightness, providing quick relief for patients with respiratory conditions.
Used in Drug Delivery Systems:
In the pharmaceutical industry, 5-(1-Methylethyl)-2-pyridinamine is used as an active ingredient in inhaler and nebulizer formulations. These drug delivery systems are designed to deliver the medication directly to the lungs, ensuring optimal therapeutic effects while minimizing systemic side effects. The development of innovative drug delivery systems for Ipratropium aims to improve patient compliance, enhance the bioavailability of the drug, and provide targeted treatment for respiratory conditions.
Overall, 5-(1-Methylethyl)-2-pyridinamine, or Ipratropium, plays a crucial role in the management of respiratory diseases such as COPD and asthma. Its effectiveness, safety, and versatility in various drug delivery systems make it a valuable asset in the field of respiratory medicine.

InChI:InChI=1/C8H12N2/c1-6(2)7-3-4-8(9)10-5-7/h3-6H,1-2H3,(H2,9,10)

Upstream product

• 82257-09-8 bromo-3 methoxy-4 pyridine 
• 1097210-49-5 tert-butyl (5-(prop-1-en-2-yl)pyridin-2-yl)carbamate 
• 159451-66-8 tert-butyl N-(5-bromopyridin-2-yl)carbamate 
• 1072-97-5 5-bromo-2-pyridylamine 
• 1135437-90-9 2-nitro-5-(prop-1-en-2-yl)pyridine 
• 603310-80-1 N-[benzyl]-2-amino-5-isopropylpyridine 
• 848841-59-8 2-amino-5-(prop-1-en-2-yl)pyridine 

Relevant academic research and scientific papers

P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS

Provided herein is novel compounds of formula (I), (II), (III), (IV), and (V) as described in the specification, and pharmaceutically acceptable salts, solvates, and prodrugs and compositions thereof, and methods of measuring hedgehog pathway activation in tumor cells, examining tumor cell proliferation, differentiation and apoptosis and using the compounds and pharmaceutical compositions disclosed for treatment of diseases and disorders associated with the hedgehog signaling pathway.

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF

The invention relates to compounds corresponding to formula (I), in the form of the base or of an acid-addition salt: in which n is equal to 0, 1, 2, 3 or 4; m is equal to 0, 1 or 2; o is equal to 0 or 1; X represents a group —CH2, —CH(R′)—, —N

ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES

Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced directly or indirectly by mutation or frameshift.

1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

This invention relates to compounds of formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.